secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001736730-25-000074
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 initiates GLP toxicology studies for CMP-SYNGAP-01; Phase 1/2 target H2 2026
--------------------------------------------------------------------------------

- Initiated GLP toxicology studies for CMP-SYNGAP-01, a regulatory RNA-targeting therapeutic for SYNGAP1-related disorders.
- Positive preclinical data: restored SYNGAP1 protein in mouse model, increased protein in brain regions of non-human primates.
- Planned CTA submission could enable first-in-human Phase 1/2 trial as early as H2 2026.
- No FDA-approved disease-modifying therapies exist for SYNGAP1-related disorders; current treatment limited to supportive care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000074/0001736730-25-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000074/camp-20251001.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer